Parkinson Disease (PD)NCT07113015
A Study Comparing Propranolol and Amantadine for Reducing Tremors in People With Parkinson's Disease
A study testing propranolol and Amantadine in people with Parkinson Disease (PD) and Tremor, run by Multan Medical And Dental College at 1 site in Pakistan.
Trial summary
Parkinson's disease is a common brain disorder in older adults that causes tremors (shaking), stiffness, and problems with movement. Among these symptoms, tremors-especially those that occur at rest-can be distressing and interfere with daily life. Read more about this study
- Who is it for?
- Ages 50 to 80 years
- Conditions the study is for
- Parkinson Disease (PD), Tremor
- What is being tested?
- propranolol and Amantadine
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 220 participants
- Where
- 1 sitePakistan
- Study dates
- 5 Jul 2024to 2 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- UK Parkinson's Disease Society Brain Bank criteria [7] - Parkinson's Disease.
- Aged between 50 and 80 years.
- Significant (resting tremor score, defined as η ≥2 on the UPDRS Part III).
- At least 4 weeks prior to the study, a stable regimen of PD medication.
Who cannot join
- Severe bradycardia, history of asthma, or heart block (used instead of the propranolol group).
- History of seizures or significant renal impairment (Amantadine group).
- Cigarette smoking, pregnant or breastfeeding women.
- Patients with MMSE < 24.
- Participation in another clinical trial at the same time.
Trial locations and contacts
1 site in 1 country.
Pakistan1 site
Multan Medical and Dental College
Multan, Punjab Province, 60000
About this study
Official title: Comparative Efficacy and Safety of Propranolol Versus Amantadine in Controlling Tremors in Parkinson's Disease: A Randomized Controlled Trial
Parkinson's disease is a common brain disorder in older adults that causes tremors (shaking), stiffness, and problems with movement. Among these symptoms, tremors-especially those that occur at rest-can be distressing and interfere with daily life. This study aims to compare two commonly used medications, propranolol and amantadine, to determine which one is more effective and safer in reducing tremors in people with Parkinson's disease.
This clinical trial was conducted with 220 adults aged 50 to 80 years who had a confirmed diagnosis of Parkinson's disease and noticeable resting tremors. Participants were randomly assigned to receive either propranolol or amantadine for 12 weeks, while continuing their usual Parkinson's medications. Tremor severity was measured using a standard scoring tool known as the Unified Parkinson's Disease Rating Scale (UPDRS). Quality of life and side effects were also closely monitored.
Read more
The hypothesis is that propranolol would be more effective in reducing tremor severity than amantadine, though it might be associated with more side effects. Both medications were given in tablet form, twice daily, and doses were adjusted based on patient response and tolerance.
At the end of the study, both groups showed improvement, but propranolol was more effective at reducing tremors. However, it caused more side effects such as tiredness and dizziness. Quality of life improved in both groups with no major difference between them. This study may help doctors decide which medication is more suitable for treating tremors in Parkinson's disease, based on the patient's health status and side effect tolerance.
- Conditions
- Parkinson Disease (PD), Tremor
- Being tested
- propranolol, Amantadine
- Keywords
- Amantadine, Parkinson's Disease, Propranolol, Motor Symptoms, Tremors
- Medical subject headings
- Parkinson Disease, Tremor
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
propranololDrug
Also called Inderal, Non-selective beta-blocker
40 mg orally twice daily, titrated up to a maximum of 80 mg/day.
AmantadineDrug
Also called Symmetrel, NMDA receptor antagonist
100 mg orally twice daily, titrated up to a maximum of 200 mg/day.
| Study group | Role | What they receive |
|---|---|---|
| Group Propranolol | Active comparator | Received 40 mg of propranolol administered orally twice daily, with dose titration permitted based on clinical response and tolerability, not exceeding 80 mg/day. PD medications remained unchanged during the trial. Receives: Drug: propranolol |
| Group Amantadine | Active comparator | Received 100 mg of amantadine administered orally twice daily, with dose titration permitted based on clinical response and tolerability, not exceeding 200 mg/day. PD medications remained unchanged during the trial. Receives: Drug: Amantadine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in tremor severity
This measure assessed the severity of resting tremor using Part III (Motor Examination) of the Unified Parkinson's Disease Rating Scale (UPDRS). Each tremor item was scored from 0 to 4, with higher scores reflecting greater severity. The change in tremor scores from baseline to week 12 was used to evaluate and compare the efficacy of propranolol and amantadine in reducing tremor severity among participants with Parkinson's disease.
Measured: From baseline to 12 weeks after intervention initiation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Aug 2025
- Study start5 Jul 2024
- Primary completion2 Dec 2024
- Study completion2 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson Disease (PD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 220 participants (actual)
Sponsor and investigators
- Lead sponsor
- Multan Medical And Dental College
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nabeel Ahmed, Multan Medical And Dental College
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07113015
- Sponsor's protocol ID
- MultanMDC1
- Status last verified
- Aug 2025
- First submitted
- 2 Aug 2025
- Last updated
- 8 Aug 2025
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Efficacy and Safety of Propranolol Versus Amantadine in Controlling Tremors in Parkinson's Disease: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07113015
- Acronym / sponsor ID
- MultanMDC1
- Conditions
- Parkinson Disease (PD), Tremor
- Keywords
- Amantadine, Parkinson's Disease, Propranolol, Motor Symptoms, Tremors
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 220 participants (actual)
- Lead sponsor
- Multan Medical And Dental CollegeUniversity, hospital or other
- Study start
- 5 Jul 2024 (actual)
- Primary completion
- 2 Dec 2024 (actual)
- Study completion
- 2 Dec 2024 (actual)
- First posted
- 8 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Parkinson's disease is a common brain disorder in older adults that causes tremors (shaking), stiffness, and problems with movement. Among these symptoms, tremors-especially those that occur at rest-can be distressing and interfere with daily life. This study aims to compare two commonly used medications, propranolol and amantadine, to determine which one is more effective and safer in reducing tremors in people with Parkinson's disease.
This clinical trial was conducted with 220 adults aged 50 to 80 years who had a confirmed diagnosis of Parkinson's disease and noticeable resting tremors. Participants were randomly assigned to receive either propranolol or amantadine for 12 weeks, while continuing their usual Parkinson's medications. Tremor severity was measured using a standard scoring tool known as the Unified Parkinson's Disease Rating Scale (UPDRS). Quality of life and side effects were also closely monitored.
The hypothesis is that propranolol would be more effective in reducing tremor severity than amantadine, though it might be associated with more side effects. Both medications were given in tablet form, twice daily, and doses were adjusted based on patient response and tolerance.
At the end of the study, both groups showed improvement, but propranolol was more effective at reducing tremors. However, it caused more side effects such as tiredness and dizziness. Quality of life improved in both groups with no major difference between them. This study may help doctors decide which medication is more suitable for treating tremors in Parkinson's disease, based on the patient's health status and side effect tolerance.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group Propranolol | Active comparator | Drug: propranololReceived 40 mg of propranolol administered orally twice daily, with dose titration permitted based on clinical response and tolerability, not exceeding 80 mg/day. PD medications remained unchanged during the trial. |
| Group Amantadine | Active comparator | Drug: AmantadineReceived 100 mg of amantadine administered orally twice daily, with dose titration permitted based on clinical response and tolerability, not exceeding 200 mg/day. PD medications remained unchanged during the trial. |
Who may qualify
- Ages
- 50 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- UK Parkinson's Disease Society Brain Bank criteria [7] - Parkinson's Disease.
- Aged between 50 and 80 years.
- Significant (resting tremor score, defined as η ≥2 on the UPDRS Part III).
- At least 4 weeks prior to the study, a stable regimen of PD medication.
Key exclusion criteria (5 listed)
- Severe bradycardia, history of asthma, or heart block (used instead of the propranolol group).
- History of seizures or significant renal impairment (Amantadine group).
- Cigarette smoking, pregnant or breastfeeding women.
- Patients with MMSE < 24.
- Participation in another clinical trial at the same time.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| propranololAlso: Inderal, Non-selective beta-blocker40 mg orally twice daily, titrated up to a maximum of 80 mg/day. | Drug | Group Propranolol |
| AmantadineAlso: Symmetrel, NMDA receptor antagonist100 mg orally twice daily, titrated up to a maximum of 200 mg/day. | Drug | Group Amantadine |
Primary outcome
Change in tremor severity
Time frame: From baseline to 12 weeks after intervention initiation
This measure assessed the severity of resting tremor using Part III (Motor Examination) of the Unified Parkinson's Disease Rating Scale (UPDRS). Each tremor item was scored from 0 to 4, with higher scores reflecting greater severity. The change in tremor scores from baseline to week 12 was used to evaluate and compare the efficacy of propranolol and amantadine in reducing tremor severity among participants with Parkinson's disease.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Aug 2025.
Related trials for Parkinson Disease (PD)
Recruiting
Automated Language Analysis in Neurodegenerative Diseases: Application of Artificial Intelligence Models
Alzheimer's Disease (AD), Frontotemporal Dementia (FTD)
Recruiting
Investigating Basal Ganglia-Cortical Physiology During Sleep and Its Modulation by Adaptive Deep Brain Stimulation in Parkinson Disease
Parkinson's Disease (PD)
Active, not recruitingPhase 2
A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease
Parkinson&Amp;#39;s Disease
RecruitingPhase 2
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
Parkinson Disease, Parkinson
RecruitingPhase 2/3
A Study of Buntanetap in Participants With PD
Parkinson's Disease (PD), Deep Brain Stimulation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing propranolol and Amantadine in people with Parkinson Disease (PD) and Tremor, run by Multan Medical And Dental College at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in tremor severity (time frame: From baseline to 12 weeks after intervention initiation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Aug 2025.